Trials / Terminated
TerminatedNCT02448095
Retrospective Evaluation of CML Patients in the National Compassionate Program
Ponatinib Survey: Retrospective Evaluation of CML Patients in the National Compassionate Program According to the 648/96 Decree
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 38 (actual)
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This observational study aims at assessing the tolerability and safety profiles of Ponatinib, a drug used for Chronic Myeloid Leukemia patients who are Philadelphia positive. This drug is used during the chronic phase of the disease, according to the Italian national compassionate law 648/96.
Detailed description
This observational study aims at assessing the tolerability and safety profiles of Ponatinib, a drug used for Chronic Myeloid Leukemia patients who are Philadelphia positive. This drug is used during the chronic phase of the disease, according to the Italian national compassionate law 648/96.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ponatinib | Observation of tolerability and safety profiles |
Timeline
- Start date
- 2015-12-22
- Primary completion
- 2018-07-17
- Completion
- 2018-07-17
- First posted
- 2015-05-19
- Last updated
- 2022-10-26
Locations
10 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT02448095. Inclusion in this directory is not an endorsement.